Investors Optimistic On FDA Panel For Novo’s Insulin Degludec
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.